Genetic editing holds promise to treat incurable diseases, but the most popular method—CRISPR—sometimes does more harm than good. A new study from University of California San Diego and Yale ...
CHICAGO, September 22, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has ...
KYOTO & FUJISAWA, Japan--(BUSINESS WIRE)--xFOREST Therapeutics Co., Ltd. (“xFOREST”) and Axcelead Drug Discovery Partners, Inc. (“Axcelead DDP”) today announced the launch of a joint research ...
Tempus AI Inc (NASDAQ:TEM) shares are trading higher Monday morning after the company announced it has received U.S. Food and Drug Administration 510(k) clearance for its RNA-based Tempus xR IVD ...
“Modeling of protein-RNA interactions in 3D is crucial, so that we know where the drug can actually target molecules that cause disease.” The promise extends well beyond viruses. By mapping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback